BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1480 related articles for article (PubMed ID: 25452219)

  • 41. Incremental diagnostic utility of gastric distension FDG PET/CT.
    Le Roux PY; Duong CP; Cabalag CS; Parameswaran BK; Callahan J; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):644-53. PubMed ID: 26487512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non-small-cell lung cancer manifesting as a subsolid nodule.
    Lee SM; Park CM; Paeng JC; Im HJ; Goo JM; Lee HJ; Kang CH; Kim YW; Kim JI
    Eur Radiol; 2012 Jul; 22(7):1556-63. PubMed ID: 22358427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDG PET Hybrid Imaging.
    Becker J; Schwarzenböck SM; Krause BJ
    Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Qualitative and quantitative performance of ¹⁸F-FDG-PET/MRI versus ¹⁸F-FDG-PET/CT in patients with head and neck cancer.
    Partovi S; Kohan A; Vercher-Conejero JL; Rubbert C; Margevicius S; Schluchter MD; Gaeta C; Faulhaber P; Robbin MR
    AJNR Am J Neuroradiol; 2014 Oct; 35(10):1970-5. PubMed ID: 24924545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole-body MR-DWIBS vs. [18F]-FDG-PET/CT in the study of malignant tumors: a retrospective study.
    Cafagna D; Rubini G; Iuele F; Maggialetti N; Notaristefano A; Pinto D; Niccoli-Asabella A; Palmiotti G; Lasciarrea M; Maggialetti A
    Radiol Med; 2012 Mar; 117(2):293-311. PubMed ID: 21744252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
    Heusch P; Nensa F; Schaarschmidt B; Sivanesapillai R; Beiderwellen K; Gomez B; Köhler J; Reis H; Ruhlmann V; Buchbender C
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):42-8. PubMed ID: 25112399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of FDG PET/ceCT in the evaluation of patients with lung cancer.
    Nanni C; Rossetti V; Zompatori M; Ambrosini V; Montesi V; Mascherini D; Pettinato C; Marzola MC; Colletti PM; Rubello D; Fanti S
    Biomed Pharmacother; 2014 Mar; 68(2):219-23. PubMed ID: 24486108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer.
    Jiang J; Yang Z; Zhang Y; Xu X; Wang M; Hu S; Yao Z; Pan H; Zhang Y; Li D
    Clin Imaging; 2014; 38(6):797-801. PubMed ID: 24973077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDG PET/CT of primary bone tumors.
    Costelloe CM; Chuang HH; Madewell JE
    AJR Am J Roentgenol; 2014 Jun; 202(6):W521-31. PubMed ID: 24848845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MR-based attenuation correction for cardiac FDG PET on a hybrid PET/MRI scanner: comparison with standard CT attenuation correction.
    Vontobel J; Liga R; Possner M; Clerc OF; Mikulicic F; Veit-Haibach P; Ter Voert EE; Fuchs TA; Stehli J; Pazhenkottil AP; Benz DC; Gräni C; Gaemperli O; Herzog B; Buechel RR; Kaufmann PA
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1574-80. PubMed ID: 26091704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
    Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
    Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.